Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 181 entries
Sorted by: Best Match Show Resources per page
Techniques for health economics analysis in oncology: Part 1.

Critical reviews in oncology/hematology

Neymark N.
PMID: 10439049
Crit Rev Oncol Hematol. 1999 Mar;30(1):1-11. doi: 10.1016/s1040-8428(98)00026-2.

No abstract available.

Cite
Neymark N. Techniques for health economics analysis in oncology: Part 1. Crit Rev Oncol Hematol. 1999;30(1):1-11doi: 10.1016/s1040-8428(98)00026-2.
Neymark, N. (1999). Techniques for health economics analysis in oncology: Part 1. Critical reviews in oncology/hematology, 30(1), 1-11. https://doi.org/10.1016/s1040-8428(98)00026-2
Neymark, N. "Techniques for health economics analysis in oncology: Part 1." Critical reviews in oncology/hematology vol. 30,1 (1999): 1-11. doi: https://doi.org/10.1016/s1040-8428(98)00026-2
Neymark N. Techniques for health economics analysis in oncology: Part 1. Crit Rev Oncol Hematol. 1999 Mar;30(1):1-11. doi: 10.1016/s1040-8428(98)00026-2. PMID: 10439049.
Copy Download .nbib Format: NLM
Cancer group denies company funding will influence its agenda.

BMJ (Clinical research ed.)

Watson R.
PMID: 17068021
BMJ. 2006 Oct 28;333(7574):874. doi: 10.1136/bmj.333.7574.874-b.

No abstract available.

Cite
Watson R. Cancer group denies company funding will influence its agenda. BMJ. 2006;333(7574):874doi: 10.1136/bmj.333.7574.874-b.
Watson, R. (2006). Cancer group denies company funding will influence its agenda. BMJ (Clinical research ed.), 333(7574), 874. https://doi.org/10.1136/bmj.333.7574.874-b
Watson, Rory. "Cancer group denies company funding will influence its agenda." BMJ (Clinical research ed.) vol. 333,7574 (2006): 874. doi: https://doi.org/10.1136/bmj.333.7574.874-b
Watson R. Cancer group denies company funding will influence its agenda. BMJ. 2006 Oct 28;333(7574):874. doi: 10.1136/bmj.333.7574.874-b. PMID: 17068021; PMCID: PMC1626281.
Copy Download .nbib Format: NLM
The economics of cancer treatment: implications for quality-of-life assessment in India.

The National medical journal of India

Gupta S, Maheshwari A.
PMID: 15253409
Natl Med J India. 2004 May-Jun;17(3):176-7.

No abstract available.

Cite
Gupta S, Maheshwari A. The economics of cancer treatment: implications for quality-of-life assessment in India. Natl Med J India. 2004;17(3):176-7
Gupta, S., & Maheshwari, A. (2004). The economics of cancer treatment: implications for quality-of-life assessment in India. The National medical journal of India, 17(3), 176-7.
Gupta, Sudeep, and Maheshwari, Amita. "The economics of cancer treatment: implications for quality-of-life assessment in India." The National medical journal of India vol. 17,3 (2004): 176-7.
Gupta S, Maheshwari A. The economics of cancer treatment: implications for quality-of-life assessment in India. Natl Med J India. 2004 May-Jun;17(3):176-7. PMID: 15253409.
Copy Download .nbib Format: NLM
The prevention and treatment (and cost) of cancer.

ACS chemical biology

Martens E.
PMID: 18041808
ACS Chem Biol. 2007 Oct 19;2(10):637-9. doi: 10.1021/cb7002169.

No abstract available.

Cite
Martens E. The prevention and treatment (and cost) of cancer. ACS Chem Biol. 2007;2(10):637-9doi: 10.1021/cb7002169.
Martens, E. (2007). The prevention and treatment (and cost) of cancer. ACS chemical biology, 2(10), 637-9. https://doi.org/10.1021/cb7002169
Martens, Eric. "The prevention and treatment (and cost) of cancer." ACS chemical biology vol. 2,10 (2007): 637-9. doi: https://doi.org/10.1021/cb7002169
Martens E. The prevention and treatment (and cost) of cancer. ACS Chem Biol. 2007 Oct 19;2(10):637-9. doi: 10.1021/cb7002169. PMID: 18041808.
Copy Download .nbib Format: NLM
From the guest editors: introduction for the impact of health care reform on cancer patients.

Cancer journal (Sudbury, Mass.)

Brawley OW, Virgo KS.
PMID: 21131784
Cancer J. 2010 Nov-Dec;16(6):551-3. doi: 10.1097/PPO.0b013e3182031591.

No abstract available.

Cite
Brawley OW, Virgo KS. From the guest editors: introduction for the impact of health care reform on cancer patients. Cancer J. 2010;16(6):551-3doi: 10.1097/PPO.0b013e3182031591.
Brawley, O. W., & Virgo, K. S. (2010). From the guest editors: introduction for the impact of health care reform on cancer patients. Cancer journal (Sudbury, Mass.), 16(6), 551-3. https://doi.org/10.1097/PPO.0b013e3182031591
Brawley, Otis W, and Virgo, Katherine S. "From the guest editors: introduction for the impact of health care reform on cancer patients." Cancer journal (Sudbury, Mass.) vol. 16,6 (2010): 551-3. doi: https://doi.org/10.1097/PPO.0b013e3182031591
Brawley OW, Virgo KS. From the guest editors: introduction for the impact of health care reform on cancer patients. Cancer J. 2010 Nov-Dec;16(6):551-3. doi: 10.1097/PPO.0b013e3182031591. PMID: 21131784.
Copy Download .nbib Format: NLM
Commentary: Implications of cancer managed as a "chronic illness".

Current oncology reports

Markman M.
PMID: 21221861
Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6.

In an increasing number of settings it is appropriate to consider cancer as a very serious but also a chronic disease process. This commentary discusses a number of highly clinically relevant implications of this important evolution in the management...

Cite
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011;13(2):90-1doi: 10.1007/s11912-010-0148-6.
Markman, M. (2011). Commentary: Implications of cancer managed as a "chronic illness". Current oncology reports, 13(2), 90-1. https://doi.org/10.1007/s11912-010-0148-6
Markman, Maurie. "Commentary: Implications of cancer managed as a "chronic illness"." Current oncology reports vol. 13,2 (2011): 90-1. doi: https://doi.org/10.1007/s11912-010-0148-6
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6. PMID: 21221861.
Copy Download .nbib Format: NLM
Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits".

The oncologist

Young RC.
PMID: 19211619
Oncologist. 2009 Feb;14(2):117-8. doi: 10.1634/theoncologist.2009-0008. Epub 2009 Feb 11.

No abstract available.

Cite
Young RC. Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits". Oncologist. 2009;14(2):117-8doi: 10.1634/theoncologist.2009-0008.
Young, R. C. (2009). Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits". The oncologist, 14(2), 117-8. https://doi.org/10.1634/theoncologist.2009-0008
Young, Robert C. "Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits"." The oncologist vol. 14,2 (2009): 117-8. doi: https://doi.org/10.1634/theoncologist.2009-0008
Young RC. Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits". Oncologist. 2009 Feb;14(2):117-8. doi: 10.1634/theoncologist.2009-0008. Epub 2009 Feb 11. PMID: 19211619.
Copy Download .nbib Format: NLM
Returning to work after parenting a child with the most curable chronic disease.

Pediatric blood & cancer

Bleyer A.
PMID: 18314902
Pediatr Blood Cancer. 2008 Jul;51(1):1-2. doi: 10.1002/pbc.21516.

No abstract available.

Cite
Bleyer A. Returning to work after parenting a child with the most curable chronic disease. Pediatr Blood Cancer. 2008;51(1):1-2doi: 10.1002/pbc.21516.
Bleyer, A. (2008). Returning to work after parenting a child with the most curable chronic disease. Pediatric blood & cancer, 51(1), 1-2. https://doi.org/10.1002/pbc.21516
Bleyer, Archie. "Returning to work after parenting a child with the most curable chronic disease." Pediatric blood & cancer vol. 51,1 (2008): 1-2. doi: https://doi.org/10.1002/pbc.21516
Bleyer A. Returning to work after parenting a child with the most curable chronic disease. Pediatr Blood Cancer. 2008 Jul;51(1):1-2. doi: 10.1002/pbc.21516. PMID: 18314902.
Copy Download .nbib Format: NLM
Balancing costs and benefits in cancer therapy and prevention.

Annals of oncology : official journal of the European Society for Medical Oncology

Szucs TD, Dedes KJ.
PMID: 18790974
Ann Oncol. 2008 Sep;19:vii313-9. doi: 10.1093/annonc/mdn475.

No abstract available.

Cite
Szucs TD, Dedes KJ. Balancing costs and benefits in cancer therapy and prevention. Ann Oncol. 2008;19:vii313-9doi: 10.1093/annonc/mdn475.
Szucs, T. D., & Dedes, K. J. (2008). Balancing costs and benefits in cancer therapy and prevention. Annals of oncology : official journal of the European Society for Medical Oncology, 19vii313-9. https://doi.org/10.1093/annonc/mdn475
Szucs, T D, and Dedes, K J. "Balancing costs and benefits in cancer therapy and prevention." Annals of oncology : official journal of the European Society for Medical Oncology vol. 19 (2008): vii313-9. doi: https://doi.org/10.1093/annonc/mdn475
Szucs TD, Dedes KJ. Balancing costs and benefits in cancer therapy and prevention. Ann Oncol. 2008 Sep;19:vii313-9. doi: 10.1093/annonc/mdn475. PMID: 18790974.
Copy Download .nbib Format: NLM
Paediatric cancer in low-income and middle-income countries.

The Lancet. Oncology

Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, Kebudi R, Macfarlane SD, Howard SC.
PMID: 23434340
Lancet Oncol. 2013 Mar;14(3):e104-16. doi: 10.1016/S1470-2045(13)70008-1. Epub 2013 Feb 20.

Patterns of cancer incidence across the world have undergone substantial changes as a result of industrialisation and economic development. However, the economies of most countries remain at an early or intermediate stage of development-these stages are characterised by poverty,...

Cite
Magrath I, Steliarova-Foucher E, Epelman S, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104-16doi: 10.1016/S1470-2045(13)70008-1.
Magrath, I., Steliarova-Foucher, E., Epelman, S., Ribeiro, R. C., Harif, M., Li, C. K., Kebudi, R., Macfarlane, S. D., & Howard, S. C. (2013). Paediatric cancer in low-income and middle-income countries. The Lancet. Oncology, 14(3), e104-16. https://doi.org/10.1016/S1470-2045(13)70008-1
Magrath, Ian, et al. "Paediatric cancer in low-income and middle-income countries." The Lancet. Oncology vol. 14,3 (2013): e104-16. doi: https://doi.org/10.1016/S1470-2045(13)70008-1
Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, Kebudi R, Macfarlane SD, Howard SC. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013 Mar;14(3):e104-16. doi: 10.1016/S1470-2045(13)70008-1. Epub 2013 Feb 20. PMID: 23434340.
Copy Download .nbib Format: NLM
Preparing for success with comparative effectiveness research.

The oncologist

Roberts TG.
PMID: 23814162
Oncologist. 2013 Jun;18(6):655-7. doi: 10.1634/theoncologist.2013-0213.

No abstract available.

Cite
Roberts TG. Preparing for success with comparative effectiveness research. Oncologist. 2013;18(6):655-7doi: 10.1634/theoncologist.2013-0213.
Roberts, T. G. (2013). Preparing for success with comparative effectiveness research. The oncologist, 18(6), 655-7. https://doi.org/10.1634/theoncologist.2013-0213
Roberts, Thomas G. "Preparing for success with comparative effectiveness research." The oncologist vol. 18,6 (2013): 655-7. doi: https://doi.org/10.1634/theoncologist.2013-0213
Roberts TG. Preparing for success with comparative effectiveness research. Oncologist. 2013 Jun;18(6):655-7. doi: 10.1634/theoncologist.2013-0213. PMID: 23814162; PMCID: PMC4063389.
Copy Download .nbib Format: NLM
[Cancer surveillance: A lot of effort with unclear benefits].

Onkologie

Becker K, Dörr W, Leiter-Stöppke U.
PMID: 22517065
Onkologie. 2012;35:8-12. doi: 10.1159/000337700. Epub 2012 Apr 23.

No abstract available.

Cite
Becker K, Dörr W, Leiter-Stöppke U. Krebsnachsorge: Viel Aufwand mit unklarem Nutzen? [Cancer surveillance: A lot of effort with unclear benefits]. Onkologie. 2012;35:8-12doi: 10.1159/000337700.
Becker, K., Dörr, W., & Leiter-Stöppke, U. (2012). Krebsnachsorge: Viel Aufwand mit unklarem Nutzen? [Cancer surveillance: A lot of effort with unclear benefits]. Onkologie, 358-12. https://doi.org/10.1159/000337700
Becker, Klaus, et al. "Krebsnachsorge: Viel Aufwand mit unklarem Nutzen?" [Cancer surveillance: A lot of effort with unclear benefits]. Onkologie vol. 35 (2012): 8-12. doi: https://doi.org/10.1159/000337700
Becker K, Dörr W, Leiter-Stöppke U. Krebsnachsorge: Viel Aufwand mit unklarem Nutzen? [Cancer surveillance: A lot of effort with unclear benefits]. Onkologie. 2012;35:8-12. doi: 10.1159/000337700. Epub 2012 Apr 23. German. PMID: 22517065.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 181 entries